Adenovirus-based vaccines - a platform for pandemic preparedness against emerging viral pathogens.
MetadataShow full item record
AbstractZoonotic viruses continually pose a pandemic threat. Infection of humans with viruses for which we typically have little or no prior immunity, can result in epidemics with high morbidity and mortality. These epidemics can have public health and economic impact, and can exacerbate civil unrest or political instability. Changes in human behavior in the past few decades: increased global travel, farming intensification, the exotic animal trade, as well as the impact of global warming on animal migratory patterns, habitats and ecosystems, contribute to the increased frequency of cross-species transmission events. Investing in the pre-clinical advancement of vaccine candidates against diverse emerging viral threats is crucial for pandemic preparedness. Replication-defective adenoviral (Ad) vectors have demonstrated their utility as an outbreak-responsive vaccine platform during the SARS-CoV-2 pandemic. Ad vectors are easy to engineer, are amenable to rapid, inexpensive manufacturing, are relatively safe and immunogenic in humans, and importantly, and do not require specialized cold-chain storage, making them an ideal platform for equitable global distribution, or stockpiling. In this review, we discuss the progress in applying Ad-based vaccines against emerging viruses, and summarize their global safety profile, as reflected by their widespread geographic use during the SARS-CoV-2 pandemic.
Rights/TermsCopyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17846
- Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses.
- Authors: Kerstetter LJ, Buckley S, Bliss CM, Coughlan L
- Issue date: 2020
- Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
- Authors: Tostanoski LH, Gralinski LE, Martinez DR, Schaefer A, Mahrokhian SH, Li Z, Nampanya F, Wan H, Yu J, Chang A, Liu J, McMahan K, Ventura JD, Dinnon KH, Leist SR, Baric RS, Barouch DH
- Issue date: 2021 Nov 9
- Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
- Authors: Lambert PH, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, Dekker CL, Didierlaurent AM, Graham BS, Martin SD, Molrine DC, Perlman S, Picard-Fraser PA, Pollard AJ, Qin C, Subbarao K, Cramer JP
- Issue date: 2020 Jun 26
- COVID-19: Prospective Challenges and Potential Vaccines.
- Authors: Shahid Nadeem M, Ali A, Al-Ghamdi MA, Depfenhart M, Azam Khan J, Zamzami MA, Nazia Murtaza B, Kazmi I, Ur Rehman M
- Issue date: 2020 Aug